Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
Jawad H. Butt, Toru Kondo, Pardeep S. Jhund, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 18, pp. 1705-1717
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction
David Chieng, Hariharan Sugumar, Louise Segan, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 6, pp. 646-658
Open Access | Times Cited: 57
Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference
Dominik Linz, Jason G. Andrade, Elena Arbelo, et al.
EP Europace (2024) Vol. 26, Iss. 4
Open Access | Times Cited: 33
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Joshua Newman, Eileen O’Meara, Michael Böhm, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 9, pp. 932-950
Closed Access | Times Cited: 23
Heart failure with preserved ejection fraction and atrial fibrillation: epidemiology, pathophysiology, and diagnosis interplay
Veraprapas Kittipibul, Carolyn S.P. Lam
Heart Failure Reviews (2025)
Closed Access | Times Cited: 2
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?
Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2112-2112
Open Access | Times Cited: 14
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1603-1614
Open Access | Times Cited: 12
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
Hongda Zhang, Lei Ding, Lijie Mi, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 7, pp. 770-779
Closed Access | Times Cited: 20
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
Stephan von Haehling, Birgit Aßmus, Tarek Bekfani, et al.
Clinical Research in Cardiology (2024) Vol. 113, Iss. 9, pp. 1287-1305
Open Access | Times Cited: 7
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
Alfredo Mauriello, Antonia Ascrizzi, Anna Selvaggia Roma, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 806-806
Open Access | Times Cited: 5
Clinical Update in Heart Failure with Preserved Ejection Fraction
Chayakrit Krittanawong, William Britt, Affan Rizwan, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 5, pp. 461-484
Closed Access | Times Cited: 4
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF
Toru Kondo, Pardeep S. Jhund, Inder S. Anand, et al.
JACC Heart Failure (2025)
Open Access
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
Qing Feng, Moya Wu, Zizhao Mai
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Finerenone and Atrial Fibrillation in Heart Failure
Shingo Matsumoto, Alasdair Henderson, Pardeep S. Jhund, et al.
JAMA Cardiology (2025)
Closed Access
Atrial fibrillation type and long-term clinical outcomes in hospitalized patients with heart failure: insight from JROADHF
Yasuhiro Hamatani, Nobuyuki Enzan, Moritake Iguchi, et al.
European Heart Journal - Quality of Care and Clinical Outcomes (2024) Vol. 10, Iss. 3, pp. 193-202
Closed Access | Times Cited: 4
Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines‐Heart Failure Registry
Ravi B. Patel, Stephen J. Greene, Haolin Xu, et al.
European Journal of Heart Failure (2022) Vol. 25, Iss. 1, pp. 63-73
Open Access | Times Cited: 17
Catheter‐based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA‐HFPEF‐DZHK27 trial
Abdul Shokor Parwani, Stefan Kääb, Tim Friede, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2203-2212
Open Access | Times Cited: 3
SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat
Nicolas Girerd, Faı̈ez Zannad
Journal of Internal Medicine (2023) Vol. 293, Iss. 5, pp. 550-558
Open Access | Times Cited: 8
Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?
Pablo Díez‐Villanueva, César Jiménez-Méndez, Ángel Pérez, et al.
Cardiology (2023) Vol. 148, Iss. 3, pp. 195-206
Open Access | Times Cited: 7
Impact of Sodium-glucose Cotransporter 2 Inhibitor on Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure
Zixu Zhao, Yiping Wang, Chao Jiang, et al.
Heart Rhythm (2024)
Closed Access | Times Cited: 2
Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta‐analysis of randomized controlled trials
Shiyue Zheng, Yiwei Lai, Chao Jiang, et al.
Pacing and Clinical Electrophysiology (2023) Vol. 47, Iss. 1, pp. 58-65
Closed Access | Times Cited: 6
Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction
Ravi B. Patel, Vivek Y. Reddy, Jan Komtebedde, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 10, pp. 1351-1362
Closed Access | Times Cited: 5
Atrial arrhythmias and heart failure: A “modern view” of an old paradox
Beniamino Pagliaro, Gianluca Mincione, Antonio Taormina, et al.
Pacing and Clinical Electrophysiology (2023) Vol. 46, Iss. 5, pp. 395-408
Open Access | Times Cited: 4
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
Carlos Escobar Cervantes, Domingo A. Pascual‐Figal, Luís Manzano, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6798-6798
Open Access | Times Cited: 4
Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities
Ghassan Bidaoui, Ala Assaf, Nassir Marrouche
Current Heart Failure Reports (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence
Junhao Lv, Luying Guo, Rending Wang, et al.
Kidney Diseases (2023) Vol. 9, Iss. 5, pp. 326-341
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top